Answers are grounded in this paper and cite their sources.
Background/Aims There is little evidence to guide the management of antiplatelets/anticoagulants (AP/AC) during endoscopic variceal band ligation (EVBL). This study aims to assess bleeding complications following EVBL performed with AP/AC. Methods We retrospectively assessed all EVBL cases performed at our centre over a 10-year period (January 2010 to August 2020), comparing outcomes of those on AP/AC during EVBL versus those not on AP/AC. Secondary analysis was of patients continuing AP/AC versus those who withheld usual AP/AC. Results A total of 1,570 episodes of EVBL were analysed (116 AP/AC, 1,454 off AP/AC). Mean age was 56.2 years, 75.6% were male, and mean model for end stage liver disease score was 14. No difference was found between groups for 30-day bleeding rates (3/116 cases [2.6%] on AP/AC, 52/1,454 cases [3.6%] off AP/AC, p =0.58), or overall 30-day mortality (3/116 cases [2.6%] on AP/AC, 18/1,454 cases [1.2%] off AP/AC, p =0.22). Similarly, 30-day bleeding rates did not differ between AP/AC patients continuing (3/110 cases [2.7%]) versus those withholding therapy (6/123 cases [4.9%], p =0.40). Conclusions In a large cohort of patients undergoing EVBL, continuation of AP/AC therapy was not associated with an elevated risk of rebleeding. This adds further evidence to support current recommendations to continue such therapy for patients undergoing endoscopy for varices.
No takes yet. Share an insight, caveat, or question.
Worland et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: